Clinical Trials Directory

Trials / Conditions / Hepatitis C (HCV)

Hepatitis C (HCV)

15 registered clinical trials studyying Hepatitis C (HCV) — 7 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingTrauma-informed, Resilience-based Telehealth Intervention for Improving HIV Prevention and HCV Care for Person
NCT06799702
University of GeorgiaN/A
Not Yet RecruitingRapid HIV, Hep C, and Syphilis Screening in a Rural Street Medicine Clinic
NCT07317687
West Virginia University—
Not Yet RecruitingCommunity Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France
NCT07038863
Hospices Civils de LyonN/A
RecruitingImplementing Low-Barrier HCV Treatment in a Jail Setting
NCT06953479
LifespanPhase 4
Not Yet RecruitingLay User Evaluation of the Panbio™ HCV Self-Test
NCT06605573
Abbott Rapid DxN/A
Not Yet RecruitingAccupower ® HCV Performance Evaluation Quant Kit Bioneer Existation™FA 96/384
NCT06623058
CerbaXpert—
RecruitingPersuasive Health Communication Intervention for HIV/HCV
NCT05968573
University of South FloridaN/A
Active Not RecruitingKentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk
NCT05657106
April M YoungN/A
CompletedA Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infect
NCT02716428
Trek Therapeutics, PBCPhase 2
CompletedA Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection
NCT02593162
Trek Therapeutics, PBCPhase 2
CompletedOmbitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On
NCT02493855
AbbViePhase 2
CompletedOmbitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatmen
NCT02476617
AbbViePhase 3
UnknownAcupuncture as an Adjunctive Treatment for Hepatitis C Patients
NCT01750515
Assy NimerN/A
CompletedABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus I
NCT01464827
AbbVie (prior sponsor, Abbott)Phase 2
CompletedStudy To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Do
NCT00651027
PfizerPhase 1